Aclaris Therapeutics/$ACRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Ticker
$ACRS
Sector
Primary listing
Employees
71
Headquarters
Website
ACRS Metrics
BasicAdvanced
$698m
-
-$0.56
0.78
-
Price and volume
Market cap
$698m
Beta
0.78
52-week high
$5.15
52-week low
$1.38
Average daily volume
1.6m
Financial strength
Current ratio
4.027
Quick ratio
4.027
Long term debt to equity
0.986
Total debt to equity
1.382
Profitability
EBITDA (TTM)
-78.469
Gross margin (TTM)
-668.18%
Net profit margin (TTM)
-832.58%
Operating margin (TTM)
-938.01%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-24.72%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
74.203
Price to book
4.86
Price to tangible book (TTM)
4.86
Price to free cash flow (TTM)
-11.874
Free cash flow yield (TTM)
-8.42%
Free cash flow per share (TTM)
-0.421
Growth
Revenue change (TTM)
-52.93%
Earnings per share change (TTM)
-61.17%
3-year revenue growth (CAGR)
-35.25%
3-year earnings per share growth (CAGR)
-27.07%
10-year earnings per share growth (CAGR)
-15.69%
What the Analysts think about ACRS
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
ACRS Financial Performance
Revenues and expenses
ACRS Earnings Performance
Company profitability
ACRS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs